Ceftazidime–Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011–2015)

    loading  Checking for direct PDF access through Ovid



Ceftazidime–avibactam was approved by the US Food and Drug Administration in 2015 to treat complicated intra-abdominal and urinary tract infections in adults and is under clinical development for treating pediatric patients.


Among 53,381 Gram-negative organisms (1 per patient) collected in 2011–2015, 8461 (15.9%) were from pediatric (≤17 years old) patients. The isolates were collected from 82 US medical centers and susceptibility tested against ceftazidime–avibactam (avibactam at fixed 4 μg/mL) and comparators by reference broth microdilution methods. Susceptibility results were stratified by patient age: ≤1 (3671 isolates); 2–5 (1900); 6–12 (1644) and 13–17 years old (1246). Enterobacteriaceae with an extended-spectrum β-lactamase (ESBL) screening-positive phenotype were evaluated by microarray-based assay for genes encoding ESBLs, KPC, NDM and transferable AmpC enzymes.


Ceftazidime–avibactam inhibited >99.9% of all Enterobacteriaceae at the ≤8 μg/mL susceptible break point and was highly active against ESBL screening–positive phenotype Escherichia coli and Klebsiella pneumoniae. Overall, 83.6% of ESBL screening–positive phenotype K. pneumoniae were susceptible to meropenem. Only 1 of 4724 Enterobacteriaceae (0.02%) isolates was nonsusceptible to ceftazidime–avibactam, an Enterobacter aerogenes with a ceftazidime–avibactam minimum inhibitory concentration (MIC) value of 16 μg/mL and negative results for all β-lactamase tested. Ceftazidime–avibactam was very active against Pseudomonas aeruginosa (MIC50/90, 1/4 μg/mL; 99.1% susceptible), including isolates nonsusceptible to meropenem (94.0% susceptible to ceftazidime–avibactam) or piperacillin–tazobactam (91.7% susceptible) or ceftazidime (89.6% susceptible). Ceftazidime–avibactam activity against P. aeruginosa did not vary substantially among age groups (98.8%–99.3% susceptible) or year of isolation (98.5%–100.0% susceptible).


Ceftazidime–avibactam was very active against a large collection of Gram-negative bacilli isolated from pediatric patients, including P. aeruginosa and Enterobacteriaceae with an ESBL screening–positive phenotype and resistant to carbapenems.

Related Topics

    loading  Loading Related Articles